AAV Dystrophin Gene Therapy Moves Into Systematic Clinical Review for Duchenne Muscular Dystrophy
A systematic review and meta-analysis in Duchenne muscular dystrophy has turned attention to one of the field’s most closely watched therapeutic strategies: adeno-associated virus, or AAV, delivery of mini- and micro-dystrophin constructs. The publication centers on a problem the disorder has long made unavoidable. Full-length dystrophin is too large to fit inside standard AAV vectors, so investigators have been forced to engineer shortened versions of the protein that preserve the most functionally important domains while staying within the packaging limits of the viral platform.
The review’s title signals a clinical question with immediate relevance for neuromuscular medicine: whether these truncated gene therapies can offer a meaningful balance of safety and efficacy in humans, not just in preclinical models. In Duchenne muscular dystrophy, the absence of dystrophin destabilizes the muscle membrane, exposes myofibers to injury during contraction, and drives a cycle of degeneration, inflammation, and fibrosis. Any therapy that restores even partial dystrophin expression aims to interrupt that process before progressive weakness becomes irreversible.
The practical appeal of mini- and micro-dystrophin approaches is easy to understand. Full-size dystrophin is enormous, but the key structural role of the protein depends on specific regions that link the cytoskeleton to the dystrophin-associated protein complex at the sarcolemma. By retaining selected domains and trimming the rest, gene engineers try to preserve enough biologic function to improve muscle stability without overloading the delivery vehicle. In theory, that strategy may reduce membrane fragility, improve resistance to contraction-induced damage, and slow the cascade that erodes skeletal and, in some cases, cardiac muscle function.
One sentence captures the entire therapeutic challenge: the gene is too large, and the disease is too severe, for a simple replacement strategy.
AAV-based delivery has emerged as the leading route for these constructs because of its ability to reach muscle tissue systemically, including across multiple muscle groups that matter in a disease as diffuse as Duchenne. Yet the same platform raises questions that cannot be dismissed. Systemic administration of high vector loads introduces exposure concerns, and the field has had to confront issues such as immune responses to the capsid, baseline immunity that may limit eligibility, and potential toxicity related to the dose needed for widespread muscle transduction. A systematic review in this area is therefore not a retrospective exercise alone; it is part of the attempt to define where the therapy fits on the risk-benefit spectrum.
The clinical significance of a meta-analysis is especially high in a rare, heterogeneous disease. Individual trials in Duchenne muscular dystrophy are often small, use different constructs, and may assess distinct biologic and functional endpoints. Pooling that evidence is one of the few ways to compare signals across studies and determine whether observed changes are consistent enough to matter for day-to-day care. Even then, interpretation remains constrained by the underlying trial designs, the maturity of follow-up, and the fact that gene therapy in Duchenne is still a relatively young field.
The review also points to a broader shift in neuromuscular therapeutics. For decades, care for Duchenne muscular dystrophy centered on corticosteroids, respiratory support, cardiac surveillance, and physical rehabilitation. Dystrophin restoration has changed the ambition of the field. Instead of only slowing decline, investigators are now trying to alter the biologic substrate of the disease itself. That ambition carries real promise, but it also demands a more exacting standard of evidence because the intervention is one-time or infrequent, technically complex, and biologically durable only if the transgene is expressed safely and persistently.
In that setting, the distinction between mini- and micro-dystrophin is not cosmetic. It reflects a strategy to preserve enough protein architecture to restore function while remaining compatible with viral delivery. Whether one construct performs better than another depends on how much of the native protein’s mechanical and signaling roles are retained, how strongly the transgene is expressed in target muscle, and how the host immune system responds once the vector is administered. Those are not abstract translational questions. They determine whether a child with Duchenne can gain measurable muscle benefit or instead absorb risk without durable functional gain.
The title of this review makes clear that the field is now moving beyond isolated trial reports and toward a more disciplined synthesis of human evidence. What the pooled clinical data show will matter for trial design, regulatory interpretation, and patient selection, especially as gene therapy pipelines continue to expand. The remaining challenge is not whether dystrophin biology matters; it does. The challenge is establishing which AAV construct, which dose, and which safety profile can justify treatment in a disease that demands both early intervention and long-term certainty.